Syngen Biotech Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
October 26, 2021
Share
Syngen Biotech Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was TWD 349.31 million compared to TWD 341.06 million a year ago. Net income was TWD 68.77 million compared to TWD 59.59 million a year ago. Basic earnings per share from continuing operations was TWD 2.54 compared to TWD 2.2 a year ago. Diluted earnings per share from continuing operations was TWD 2.54 compared to TWD 2.2 a year ago.
For the nine months, sales was TWD 1,038.97 million compared to TWD 978.86 million a year ago. Net income was TWD 171.26 million compared to TWD 174.39 million a year ago. Basic earnings per share from continuing operations was TWD 6.32 compared to TWD 6.43 a year ago. Diluted earnings per share from continuing operations was TWD 6.31 compared to TWD 6.43 a year ago.
Syngen Biotech Co Ltd is a Taiwan-based company mainly engaged in the manufacture and distribution of active pharmaceutical ingredients and health food products. The Companyâs products mainly consist of active pharmaceutical ingredients, health food raw materials, medical equipment, such as bone density analyzers, blood glucose analyzers and biochemical analyzers, as well as animal health products and others. The Company distributes its products mainly in Taiwan, Iran, South Korea and Egypt.